Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The REaCT-CHRONO-MetBP Pilot study will compare morning and evening administration of endocrine-based therapy in metastatic breast and prostate cancers. Participants with metastatic breast or prostate cancer will be randomly placed in one of two groups: a morning group and an evening group. The group assignment will determine whether they take their endocrine therapy in the morning or the evening. The primary outcome of this pilot study is to evaluate the feasibility of study procedures in order to conduct a larger definitive trial in the future. The secondary outcomes include comparing quality of life, tolerability, and efficacy outcomes between the morning and evening groups for each of the two cancer cohorts (metastatic breast and prostate cancer).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci z rakiem piersi przerzutowym receptorem hormonalnym dodatnim
- •Plan leczenia hormonalnego i inhibitorem CDK4/6 (Ribociclib lub Palbociclib) jako pierwsza linia
- •Wiek 18 lat lub więcej
- •Możliwość udzielenia ustnej zgody
- •Chęć i możliwość wypełniania ankiet zgodnie z protokołem badania
- •Pacjenci z rakiem prostaty przerzutowym wrażliwym na kastację
- •Plan leczenia inhibitorem szlaku receptora androgenowego (enzalutamid, apaluramid lub octan abireateronu) w połączeniu z terapią depresji androgenowej
- •Możliwość wykonywania testów zgodnie z harmonogramem badania
✗ Disqualifies
- •Przeciwwskazania do przyjmowania leków rano lub wieczorem
- •Plan przyjmowania abemaciclibu (wymagającego dawkowania dwa razy dziennie)
- •Plan przyjmowania darolutamidu (wymagającego dawkowania dwa razy dziennie)
- •Plan chemioterapii docetakselem w połączeniu z inhibitorem szlaku receptora androgenowego
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Waterloo Regional Health Network
Kitchener, Canada
The Ottawa Hospital Cancer Centre
Ottawa, Canada
Saskatoon Cancer Centre
Saskatoon, Canada
Trial contact
Lisa Vandermeer, MSc
Deanna Saunders, MSc
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.